La chaîne d'options affiche les données clés des options sur actions de Cresco Labs à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Cresco Labs..

Cresco Labs (OTC:CRLBF) Stock, Chaîne d'Options

Cresco Labs

Cresco Labs Inc is a vertically-integrated multi-state cannabis operator in the United States licensed to cultivate, manufacture and sell retail and medical cannabis products through Sunnyside, Cresco Labs' national dispensary brand and others. The company operates in one segment, the cultivation, manufacturing, distribution and sale of cannabis.

Cresco Labs Inc

Bel Fuse (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BELFB#NASDAQ">BELFB</a>) reported quarterly earnings of $1.35 per share which beat the analyst consensus estimate of $0.94 by 43.62 percent. This is a 7.14 percent increase over earnings of $1.26 per share from the same period last year. The company reported quarterly sales of $152.24 million which beat the analyst consensus estimate of $130.25 million by 16.88 percent. This is a 18.85 percent increase over sales of $128.09 million the same period last year.

Earnings

Earnings Beats

News

BELFB

Bel Fuse Q1 Adj. EPS $1.35 Beats $0.94 Estimate, Sales $152.24M Beat $130.25M Estimate

Barclays analyst Lauren Lieberman maintains Kimberly-Clark (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMB#NYSE">KMB</a>) with a Equal-Weight and lowers the price target from $139 to $135.

Price Target

Analyst Ratings

Barclays Maintains Equal-Weight on Kimberly-Clark, Lowers Price Target to $135

Bel Fuse (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BELFA#NASDAQ">BELFA</a>) reported quarterly earnings of $1.28 per share which beat the analyst consensus estimate of $1.15 by 11.3 percent. This is a 7.56 percent increase over earnings of $1.19 per share from the same period last year. The company reported quarterly sales of $152.24 million which beat the analyst consensus estimate of $147.25 million by 3.39 percent. This is a 18.85 percent increase over sales of $128.09 million the same period last year.

BELFA

Bel Fuse Q1 Adj. EPS $1.28 Beats $1.15 Estimate, Sales $152.24M Beat $147.25M Estimate

If you had $100,000 sitting in your account, what would you do with it? Buy a house? Dump it into stocks? Pay off your student loans and go on a Target spree with what's left?
In a <a href="https://www.forbes.com/2010/11/03/billionare-mark-cuban-entrepreneur-dallas-mavericks-secrets-self-made-10.html">2010 Forbes interview</a>, billionaire Mark Cuban—longtime "Shark Tank" star and the guy now trying to <a href="https://www.benzinga.com/personal-finance/25/04/44839817/billionaire-mark-cuban-says-pharma-is-the-easiest-business-ive-ever-disrupted-in-a-500-billion-industry-1-is-a-whole-lot-of-money">shake up Big Pharma</a>—offered his take. And spoiler: it's not what the TikTok finance gurus are preaching.
Instead of pouring it into the market or investing in a startup, Cuban said this:
"First I <a href="https://www.benzinga.com/personal-finance/24/11/42248381/mark-cuban-insists-credit-cards-are-not-your-friend-and-proposes-taking-out-a-personal-loan-for-expenses-instead-is-this-a-smart-move">pay off all my credit card debt</a> and evaluate paying off any other debt I have. What I have left I put in the bank."
Don't Miss:
<ul>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a></li>
<li><a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.</li>
</ul>
That's right. The man who made billions selling Broadcast.com to Yahoo in the 1990s says step one is killing your debt. Step two? Parking your leftover cash in the bank—not because it'll grow, but because it'll wait.
His strategy is equal parts frugal and sharp. He adds, "Then I try to create as much transactional value as possible from that cash."
He looks at his entire budget and finds savings in boring but necessary stuff—like "<a href="https://www.benzinga.com/personal-finance/25/03/44065932/mark-cuban-was-asked-how-hed-invest-100k-his-answer-buy-bulk-toothpaste-and-soup-for-the-best-guaranteed-return-on-investment">toothpaste to soup</a>." Buying in bulk, he argues, gives you the best guaranteed ROI anywhere, sometimes saving you 30% to 50% on everyday items. That's your safest return, Cuban says. Better than trying to time the market.
Trending: BlackRock is calling 2025 the year of alternative assets. <a href="https://www.benzinga.com/money/masterworks">One firm from NYC has quietly built a group of 60,000+ investors who have all joined in on an alt asset class previously exclusive to billionaires like Bezos and Gates.</a>
Cuban says, "Every five years or so there is a bubble bursting or amazing deals available because of a change in the economy." That might sound dramatic, but the pattern isn't entirely off. Look at the timeline:
<ul>
<li>2025: Commercial real estate's under pressure, VC funding has slowed, and inflation is still hanging around.</li>
<li>2020: COVID-19 hits. Stocks tank. Unemployment soars. Stimulus money floods the system.</li>
<li>2015: Oil prices plunge, China's stock market crashes, and U.S. markets stumble in a major late-summer selloff.</li>
<li>2010: The housing market's still reeling from the 2008 crash. Banks are shaky. Foreclosures peak.</li>
<li>2005: U.S. housing bubble in full swing—just two years before the subprime mortgage crisis begins to unwind.</li>
<li>2000: The dot-com bubble bursts. NASDAQ loses nearly 80% of its value in two years.</li>
<li>1995: Tech stocks start to soar, fueled by early internet hype. Just five years later—boom.</li>
</ul>
His advice might not be about nailing the exact timing—it's more about being ready when the shift happens.
Cuban continued, "Anyone who just kept their cash in the bank rather than in stocks over the past five to 10 years could be buying the home of their dreams for half price in most of the country."
See Also: Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.60 per share now</a>.
At the time, that wasn't an exaggeration. Following the housing crash, home prices had dropped dramatically, and interest rates—while not rock-bottom yet—were already sliding. His point wasn't about chasing returns in a savings account. It was about having dry powder when the rest of the market was drowning.
"They earned good money in half the past 10 years on the cash… and even though they aren't making much now, they have the transactional value available to them. Plus they have <a href="https://www.benzinga.com/personal-finance/25/02/43885487/billionaire-mark-cuban-said-the-first-step-to-getting-rich-is-giving-things-up-drink-water-eat-mac-and-cheese-and-save-every-penny">cash to invest if the market craters </a>and, most importantly, they sleep great at night."
And then comes the mic drop line: "Cash is king—and works far better than Ambien when you want a good night's sleep every night."
So is Cuban right? Depends who you ask. But if history really does crack every five years, and you're debt-free with cash on standby, you might be the one scooping up deals while everyone else is scrambling. And that sounds pretty Shark-like.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/money/mark-cubans-advice-for-lotto-winners">Many are surprised by Mark Cuban's advice for lotto winners: Cash or annuity?</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
</ul>
Image: Shutterstock

Personal Finance

Mark Cuban Was Asked What He'd Do With $100K: 'Put It In the Bank' Because Every 5 Years, A Bubble Bursts Or Game-Changing Deals Appear

Gilead Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) released its first-quarter results after Thursday's closing bell. Here's a look at the details<a href="https://www.benzinga.com/pressreleases/25/04/b44994576/gilead-sciences-announces-first-quarter-2025-financial-results"> from the report. </a>
The Details: Gilead Sciences reported quarterly earnings of $1.81 per share, which beat the analyst consensus estimate of $1.76. Quarterly revenue came in at $6.67 billion, which missed the analyst consensus estimate of $6.77 billion and is a decrease from revenue of $6.69 billion year-over-year.
Read Next: <a href="https://www.benzinga.com/news/global/25/04/44952117/apple-and-meta-fined-nearly-800-million-for-violating-european-unions-digital-markets-act?utm_source=articleShare">Apple And Meta Fined Nearly $800 Million For Violating European Union&#8217;s Digital Markets Act</a>&nbsp;
For the first quarter, the company reported: 
<ul>
<li>HIV product sales increased 6% to $4.6 billion in the first quarter of 2025 compared to the same period in 2024, primarily driven by higher average realized price and demand.</li>
<li>Liver Disease portfolio sales increased 3% to $758 million in the first quarter of 2025 compared to the same period in 2024. This was primarily driven by increased demand in products for primary biliary cholangitis, chronic hepatitis B virus and chronic hepatitis delta virus, partially offset by lower average realized price for chronic hepatitis C virus products.</li>
<li>Veklury sales decreased 45% to $302 million in the first quarter of 2025 compared to the same period in 2024, primarily driven by lower rates of COVID-19-related hospitalizations across regions.</li>
<li>Cell Therapy&nbsp;product sales decreased 3% to $464 million in the first quarter 2025 compared to the same period in 2024.</li>
</ul>
&#8220;Gilead had a strong start to the year driven by excellent commercial and clinical execution along with disciplined expense management,&#8221; said Daniel O&#8217;Day, Gilead&#8217;s CEO.
&#8220;Our base business grew 4% year-over-year, primarily led by Biktarvy&#8217;s continued strength, and we announced positive topline Phase 3 results for Trodelvy plus pembrolizumab in first line PD-L1+ metastatic triple negative breast cancer,&#8221; O&#8217;Day added. 
Outlook:&nbsp;Gilead Sciences lowered its fiscal 2025 earnings guidance from a range of $5.95 to $6.35 per share to&nbsp;a range of $5.65 to $6.05&nbsp;per share, versus the $6.21&nbsp;estimate. 
GILD Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Gilead Sciences stock was down 3.34% after hours at $102.70 on Thursday.  
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44956197/amazon-price-target-slashed-again-on-wild-card-tariff-concerns?utm_source=articleShare">Amazon Price Target Slashed Again On &#8216;Wild Card&#8217; Tariff Concerns&nbsp;</a></li>
</ul>
Photo: Shutterstock

Biotech

Health Care

After-Hours Center

Movers

General

GILD

Gilead Sciences Stock Slips After Mixed Q1 Results, Lowered FY25 EPS Guidance

Rosenblatt analyst Catharine Trebnick maintained RingCentral (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RNG#NYSE">RNG</a>) with a Buy and lowered the <a target="_blank" href="https://www.benzinga.com/quote/RNG/analyst-ratings" rel="noreferrer noopener">price forecast from&nbsp;$40&nbsp;to&nbsp;$28</a> on Thursday.
Trebnick reduced her price forecast due to lower revenue projections for fiscal 2025 and 2026, reflecting ongoing economic uncertainty and recent leadership transitions.
The analyst remarked RingCentral as a stock for patient investors.
Also Read: <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/04/44878679/whats-going-on-with-zoom-shares-today" rel="noreferrer noopener">Zoom Shares Rise After Global Outage Reminds Investors of Platform&#8217;s Reach and Reliability Stakes</a>
The new products are gaining traction, but she expected slower growth with the economic backdrop and increased competition across the partner channel.
The new price forecast of $28 (from $40) reflects ~1.5 times (from ~2 times) Trebnick&#8217;s revenue estimate of 6% Y/ Y in fiscal 2026.
RingCentral&#8217;s stock is trading at 1.3 times EV/calendar 2026 Sales, which are growing at 6% Y/Y, and a discount to its CCaaS group average of 2.5 times, which is growing at 8% Y/Y.
The analyst decreased her fiscal 2025 revenue growth rate to 4.4%, which is below the low point of the guidance (+5% CC growth).
Trebnick&#8217;s fiscal 2025 estimate has been revised to $2.506 billion (+4.4% growth) from $2.510 billion (+4.6% growth) and below the Street&#8217;s $2.516 billion (+4.8% growth).
Similarly, the analyst decreased her fiscal 2026 estimate to $2.656 billion (+6% growth) from $2.680 billion (+7% growth), which is below the Street&#8217;s $2.665 billion (+6% growth).
For fiscal 2025, Trebnick&#8217;s operating income moves to $561 million (22.4% margin), down from ($563 million) and below the current Street estimate ($565 million).
For fiscal 2026, the analyst&#8217;s adjusted operating income is $623 million (23.5% margin), just slightly below the current Street estimate of $622 million (23.3% margin).
Due to the deceleration of sales volume, Trebnick adjusted her fiscal 2025 adjusted EPS to $4.19 (from $4.20).
Looking ahead to fiscal 2026, the analyst&#8217;s adjusted EPS of $4.66 (down from $4.70) and below the current Street estimate of $4.68.
The three modules, RingCX, RingEvents, and RingSense, are expected to drive $100 million in ARR in fiscal 2025, and with this strong start, Trebnick anticipates this will be incremental to the target.
RingCX has gone +700 in one year. RingCentral has introduced several new products, AI Interaction Analytics, AI Agent Assist, and AI Supervisor Assist, which should drive incremental revenue in the second half of 2025 and into fiscal 2026.
Price Action: RNG stock closed higher by 6.38% to $25.01 on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/44978860/stmicro-calls-out-bottom-in-q1-forecasts-q2-rebound-focusing-on-cost-cuts" target="_blank" rel="noreferrer noopener">STMicro Calls Out Bottom In Q1, Forecasts Q2 Rebound Focusing On Cost Cuts</a></li>
</ul>

Analyst Color

Reiteration

Trading Ideas

RingCentral A Stock for Patient Investors, AI Tools And New Products Show Early Promise: Analyst

Blue Ridge Bankshares (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BRBS#AMEX">BRBS</a>) reported quarterly losses of $(0.01) per share. This is a 93.33 percent increase over losses of $(0.15) per share from the same period last year.

BRBS

Blue Ridge Bankshares Q1 EPS $(0.01) Up From $(0.15) YoY

Barclays analyst Matt Miksic maintains Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) with a Overweight and lowers the price target from $684 to $635.

ISRG

Barclays Maintains Overweight on Intuitive Surgical, Lowers Price Target to $635

Jefferies analyst John Hecht maintains Bread Finl Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFH#NYSE">BFH</a>) with a Hold and raises the price target from $45 to $50.

Jefferies Maintains Hold on Bread Finl Hldgs, Raises Price Target to $50

Jefferies analyst Anna Glaessgen maintains Brunswick (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BC#NYSE">BC</a>) with a Hold and lowers the price target from $64 to $45.

Jefferies Maintains Hold on Brunswick, Lowers Price Target to $45

<a href="https://www.reuters.com/world/trump-poised-offer-saudi-arabia-over-100-bln-arms-package-sources-2025-04-24/">https://www.reuters.com/world/trump-poised-offer-saudi-arabia-over-100-bln-arms-package-sources-2025-04-24/</a>

'Trump poised to offer Saudi Arabia over $100B arms package'- Reuters News

Compass Point analyst Casey Alexander downgrades RLI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RLI#NYSE">RLI</a>) from Buy to Neutral and lowers the price target from $82 to $76.

Downgrades

Compass Point Downgrades RLI to Neutral, Lowers Price Target to $76

NewMarket Corporation Announces Approval Of Up To $100M To Expand Ampac's Ammonium Perchlorate Production Capabilities In Support Of Growing Solid Rocket Motor Demand

Nu will continue operating as a SOFIPO during its transformation process, providing the same seamless user experience ahead of beginning operations as a bank
The license marks a key step for Nu to increase competition in the highly concentrated Mexican banking market
Nu Mexico, a subsidiary of Nubank, announced today the approval of its banking license by the National Banking and Securities Commission (CNBV). With this milestone, Nu has become the first Popular Financial Society (SOFIPO) to obtain approval to transform into a bank, opening the path to increased competition in the Mexican financial sector. This milestone brings the company closer to expanding its product portfolio, including the introduction of a payroll account, a key opportunity to increase financial inclusion in Mexico where only 36% of adults have this financial instrument (National Financial Inclusion Survey, 2024), with 90% concentrated in just four banks.

Global

Nu Mexico Becomes First SOFIPO Approved To Transform Into A Bank, Marking Major Step Toward Boosting Competition And Financial Inclusion In Mexico's Banking Sector

HONE

Trading Halt: Halt status updated at 5:10:00 PM ET: Quotation Resumption: News and Resumption Times

FreightCar America, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAIL#NASDAQ">RAIL</a>) ("FreightCar America" or the "Company"), a diversified manufacturer and supplier of railroad freight cars, railcar parts, and components, today announced that it received total orders valued at approximately $141 million, representing a total of 1,250 railcars, during the quarter ended March 31, 2025. These orders underscore ongoing demand for FreightCar America's railcar offerings and reflect continued market share gains.
FreightCar America continues to gain share within its core railcar markets, driven by strategic initiatives aimed at increasing operational efficiency, product innovation, and commercial excellence. The orders represent approximately 25% of all new railcars ordered in the quarter, and 36% in our addressable market, marking the largest new railcar market share quarter intake in 15 years.

Contracts

RAIL

FreightCar America Announces Orders Of 1,250 Railcars Valued At $141M

Agnico Eagle Mines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEM#NYSE">AEM</a>) reported quarterly earnings of $1.53 per share which beat the analyst consensus estimate of $1.28 by 19.53 percent. This is a 101.32 percent increase over earnings of $0.76 per share from the same period last year. The company reported quarterly sales of $2.47 billion which beat the analyst consensus estimate of $2.41 billion by 2.49 percent. This is a 34.86 percent increase over sales of $1.83 billion the same period last year.

Agnico Eagle Mines Q1 Adj. EPS $1.53 Beats $1.28 Estimate, Sales $2.47B Beat $2.41B Estimate

Alpine Income Property Tr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PINE#NYSE">PINE</a>) raises FY2025 FFO guidance from $1.70-$1.73 to $1.74-$1.77 vs $1.73 analyst estimate..

Guidance

PINE

Alpine Income Property Tr Raises FY2025 FFO Guidance from $1.70-$1.73 to $1.74-$1.77 vs $1.73 Est

PCLA

PicoCELA  Receives Nasdaq Letter Regarding Minimum Bid Price Deficiency

Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBBK#NASDAQ">TBBK</a>) reported quarterly earnings of $1.19 per share which missed the analyst consensus estimate of $1.24 by 4.03 percent. This is a 12.26 percent increase over earnings of $1.06 per share from the same period last year. The company reported quarterly sales of $91.74 million which missed the analyst consensus estimate of $94.55 million by 2.97 percent. This is a 2.83 percent decrease over sales of $94.42 million the same period last year.

Comments

Cresco Labs

Cresco Labs (CRLBF) Options

No option chain data available. Please try again later

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL